# Candesartan Effect in Second Stage Arterial Hypertension

> **NCT00621153** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 214 (actual)

## Conditions studied

- Stage II Hypertension

## Interventions

- **DRUG:** Candesartan Cilexetil
- **DRUG:** Hydrochlorothiazide
- **DRUG:** Candesartan Cilexetil

## Key facts

- **NCT ID:** NCT00621153
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2010-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621153, "Candesartan Effect in Second Stage Arterial Hypertension". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00621153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*